文献速递造血干细胞移植与细胞治疗

Cereblon调控CD8+ T淋巴细胞的Myc依赖性生物能量与活性

Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes.
PubMed 文献 · Blood · 2020-01-01

该研究探讨CRBN在CD8+ T细胞效应应答中的内源性作用。小鼠CD8+ T细胞中Crbn缺失可增强中央代谢,表现为生物能量升高、多胺超生理水平、葡萄糖和氨基酸转运增强及代谢酶表达增加;CRBN调节药物同样增强人CD8+ T细胞代谢,且与MYC表达增加和持续相关。Crbn缺失T细胞在体外和体内对黑色素瘤细胞的抗原特异性杀伤活性增强,并驱动加速且高度侵袭性的移植物抗宿主病。

要点

  • Crbn缺失小鼠CD8+ T细胞中央代谢增强,多胺达超生理水平,葡萄糖和氨基酸转运增强。
  • CRBN调节药物增强人CD8+ T细胞中央代谢,与MYC表达增加和持续相关。
  • Crbn缺失T细胞体外和体内抗原特异性杀伤黑色素瘤细胞增强,并驱动加速且高度侵袭性GVHD。

核心结论

  • CRBN在负反馈环路中约束CD8+ T细胞活化,该表型可被CRBN调节药物治疗所利用。

研究设计与样本

  • 研究在鼠源CD8+ T细胞中采用Crbn缺失,并用人CD8+ T细胞经CRBN调节化合物处理,结合体外和体内功能实验。

主要发现

  • Crbn缺失小鼠CD8+ T细胞中央代谢增强,生物能量升高,多胺达超生理水平,继发于葡萄糖和氨基酸转运增强。
  • Crbn缺失小鼠CD8+ T细胞代谢酶表达增加,包括多胺生物合成酶鸟氨酸脱羧酶。
  • CRBN调节化合物处理同样增强人CD8+ T细胞中央代谢。
  • 通过调节化合物或Crbn缺失对CD8+ T细胞的代谢控制与主代谢调节因子MYC表达增加和持续相关。
  • Crbn缺失T细胞体外和体内对黑色素瘤细胞的抗原特异性杀伤活性增强,并驱动加速且高度侵袭性的移植物抗宿主病。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunomodulatory drugs, such as thalidomide and related compounds, potentiate T-cell effector functions. Cereblon (CRBN), a substrate receptor of the DDB1-cullin-RING E3 ubiquitin ligase complex, is the only molecular target for this drug class, where drug-induced, ubiquitin-dependent degradation of known "neosubstrates," such as IKAROS, AIOLOS, and CK1α, accounts for their biological activity. Far less clear is whether these CRBN E3 ligase-modulating compounds disrupt the endogenous functions of CRBN. We report that CRBN functions in a feedback loop that harnesses antigen-specific CD8+ T-cell effector responses. Specifically, Crbn deficiency in murine CD8+ T cells augments their central metabolism manifested as elevated bioenergetics, with supraphysiological levels of polyamines, secondary to enhanced glucose and amino acid transport, and with increased expression of metabolic enzymes, including the polyamine biosynthetic enzyme ornithine decarboxylase. Treatment with CRBN-modulating compounds similarly augments central metabolism of human CD8+ T cells. Notably, the metabolic control of CD8+ T cells by modulating compounds or Crbn deficiency is linked to increased and sustained expression of the master metabolic regulator MYC. Finally, Crbn-deficient T cells have augmented antigen-specific cytolytic activity vs melanoma tumor cells, ex vivo and in vivo, and drive accelerated and highly aggressive graft-versus-host disease. Therefore, CRBN functions to harness the activation of CD8+ T cells, and this phenotype can be exploited by treatment with drugs.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hesterberg RS, Beatty MS, Han Y, et al. Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes. Blood. 2020. PMID: 32403132. doi:10.1182/blood.2019003257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。